Si prevede che il mercato della steatoepatite non alcolica (NASH) raggiungerà i 24.266,81 milioni di dollari entro il 2028 rispetto ai 1.631,92 milioni di dollari del 2021; si prevede che registrerà un CAGR del 47,1% dal 2021 al 2028.
Nella steatosi epatica non alcolica (NAFLD), il grasso si accumula nel fegato. Il fegato grasso non alcolico (NAFL) e la steatoepatite non alcolica (NASH) sono tipi di NAFLD. Quando l’accumulo di grasso provoca infiammazioni e danni, porta allo sviluppo della NASH, che può portare alla cicatrizzazione del fegato. La cicatrizzazione del fegato è una condizione potenzialmente pericolosa per la vita chiamata cirrosi.
Il rapporto offre approfondimenti e analisi approfondite del mercato della steatoepatite non alcolica (NASH), sottolineando vari parametri come le tendenze del mercato, i progressi tecnologici e le dinamiche di mercato. Fornisce inoltre l’analisi del panorama competitivo dei principali attori del mercato in tutto il mondo. Inoltre, include l’impatto della pandemia COVID-19 sul mercato in tutte le regioni. La pandemia di COVID-19 ha sconvolto le condizioni socioeconomiche di vari paesi in tutto il mondo. In Nord America, gli Stati Uniti sono stati profondamente colpiti dalla pandemia di COVID-19. Il danno epatico sotto forma di aumento delle transaminasi e iperbilirubinemia tra i pazienti affetti da COVID-19 può essere attribuito a un paio di fattori, tra cui una malattia epatica preesistente. La comorbilità della steatosi epatica non alcolica (NAFLD) e della NASH in questi pazienti li rende soggetti a gravi forme di danno epatico. Data l’elevata prevalenza della NAFLD in tutto il mondo, è di gran lunga fondamentale riconoscere i risultati del COVID-19 in tali pazienti, che includono il ruolo delle comorbidità, della progressione della malattia e della gravità del COVID. La presenza di fibrosi piuttosto che di NASH/NAFLD è associata a esiti clinici peggiori e a una mortalità più elevata nei pazienti con COVID-19.
L'impatto di COVID-19 sulle popolazioni di pazienti in comorbidità , comprese le persone con diabete, obesità, malattia del fegato grasso e NASH, ha innescato la necessità di fornire cure ottimali ai pazienti. Il Global Liver Institute è impegnato a collaborare con ricercatori e innovatori in tutto il mondo per valutare e formulare rapidamente una risposta forte a questa pandemia. La ricerca che ruota attorno alla lotta alla NAFLD e alla NASH indica che la relazione prevista con i problemi di peso è netta. Pertanto, un’elevata incidenza della NASH richiede diagnosi e trattamenti avanzati, che stimolano la ricerca e lo sviluppo sul mercato. Pertanto, la crisi del COVID-19 ha alimentato la crescita del mercato della steatoepatite non alcolica (NASH).
Approfondimenti strategici
Regioni redditizie per il mercato della steatoepatite non alcolica (NASH)
Approfondimenti di mercato
Le crescenti iniziative per aumentare la consapevolezza della NASH guidano la crescita del mercato
La NASH è una condizione sottoriconosciuta. Per un percorso di riferimento strutturato e una diagnosi precoce, è essenziale creare una maggiore consapevolezza di questa malattia tra il pubblico in generale e i medici di base (PCP). Stabilendo un chiaro percorso dei pazienti per le segnalazioni e campagne di sensibilizzazione dei pazienti, è possibile identificare più individui e inviarli agli specialisti per un'ulteriore valutazione. Per aumentare la consapevolezza sulla NASH, il NASH Education Program ha lanciato la campagna di educazione pubblica il 12 giugno 2018, celebrata come la "Giornata internazionale della NASH", per aumentare la consapevolezza sulla NAFLD e sulla sua forma più avanzata, la NASH, che colpisce oltre circa 115 milioni di persone persone.
NASH 24X7, una piattaforma digitale volta ad aumentare l'esposizione e la consapevolezza riguardo all'epidemia di NASH, ha compiuto alcuni passi in occasione della Giornata internazionale della NASH 2019 attraverso il supporto degli operatori sanitari e la sensibilizzazione dei pazienti e programmi di comunicati stampa/TV. Per sensibilizzare l'opinione pubblica in questa giornata, i NASH Crusaders della NASH 24X7 si sono uniti ai migliori operatori sanitari (HCP), in particolare gastroenterologi ed epatologi, in tutta l'India per organizzare numerose iniziative di sensibilizzazione e di sensibilizzazione su piccola e larga scala. seminari educativi sulla salute del fegato, evidenziando la necessità di uno stile di vita sano nella prevenzione della NAFLD/NASH.
In occasione della Giornata internazionale della NASH 2020, l'American Liver Foundation si è unita a una comunità globale per aumentare la consapevolezza sulla NASH con il supporto della Fondazione Allergan. L'American Liver Foundation (ALF) sta ora sperimentando un programma di messaggistica di testo NASH, in cui le persone possono iscriversi per ricevere 3 messaggi settimanali per 10 settimane. I messaggi consistono in collegamenti ipertestuali a risorse NASH, fatti rilevanti, quiz interattivi e indicazioni sensate per l'autogestione quotidiana. L'ALF aprirà questo sistema al grande pubblico una volta terminato e valutato il progetto pilota. Ha collaborato con il Global Liver Institute (GLI) in occasione della Giornata internazionale della NASH e ha condiviso alcuni post sui social media collegati ai post del GLI e alla pagina della Giornata internazionale della NASH.
Così , le crescenti iniziative per promuovere la consapevolezza riguardo alla NASH stanno guidando il mercato della steatoepatite non alcolica (NASH).
Approfondimenti basati sul prodotto
Basati Sul prodotto, il mercato della steatoepatite non alcolica (NASH) è segmentato in vitamina E e pioglitazone, ocaliva, elafibranor, selonsertib e amp; cenicriviroc e altri. Nel 2021, il segmento altri deteneva la quota maggiore del mercato. Il selonsertib & Si prevede che il segmento cenicriviroc registrerà il CAGR più rapido pari al 73,3% durante il periodo di previsione.
Mercato delle soluzioni per la conservazione degli organi, per prodotto: 2020 e 2028
Approfondimenti basati sull'applicazione
In base all'applicazione, il mercato della steatoepatite non alcolica (NASH) è diviso in trattamento e diagnosi. Nel 2021, il segmento del trattamento deteneva una quota maggiore del mercato. Tuttavia, si prevede che il segmento del trattamento registrerà un CAGR più elevato pari al 47,3% durante il periodo di previsione.
Approfondimenti basati sul canale di vendita
Basato su canale di vendita, il mercato della steatoepatite non alcolica (NASH) è segmentato in farmacia ospedaliera, farmacia al dettaglio e fornitore online. Nel 2021, il segmento delle farmacie al dettaglio deteneva la quota maggiore del mercato. Inoltre, si prevede che il segmento delle farmacie al dettaglio registrerà il CAGR più elevato, pari al 47,2%, nel periodo dal 2021 al 2028.
Gli operatori del mercato della steatoepatite non alcolica (NASH) adottano strategie organiche come il lancio e l'espansione dei prodotti per espandere la propria presenza e il portafoglio prodotti in tutto il mondo, nonché per soddisfare le crescenti richieste.
Per area geografica
Basato In termini geografici, il mercato della steatoepatite non alcolica (NASH) è segmentato in Nord America (Stati Uniti, Canada e Messico), Europa (Regno Unito, Germania, Francia, Italia, Spagna e resto d’Europa), Asia Pacifico (Cina, Giappone , India, Australia, Corea del Sud e resto dell'Asia Pacifico), Medio Oriente e altri paesi. Africa (Emirati Arabi Uniti, Arabia Saudita, Sud Africa e resto del Medio Oriente e dell'Africa) e Sud e Africa. America centrale (Brasile, Argentina e resto dell'America meridionale e centrale).
Profili aziendali
- Genfit SA
- One Way Liver, SL
- BioPredictive SAS
- Cadila Pharmaceuticals Ltd.
- Prometheus Laboratories
- Siemens Healthineers AG
- Intercept Pharmaceuticals, Inc.
- Novartis AG
- Galmed Pharmaceuticals
- Laboratory Corporation of America Holdings
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
This text is related
to segments covered.
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
Frequently Asked Questions
Nonalcoholic fatty liver disease (NAFLD) is a condition in which fat builds up in your liver. Nonalcoholic fatty liver (NAFL) and nonalcoholic steatohepatitis (NASH) are types of NAFLD. Non-alcoholic steatohepatitis (NASH) is an advanced form of non-alcoholic fatty liver disease (NAFLD). NAFLD is caused by buildup of fat in the liver. When this buildup causes inflammation and damage, it is known as NASH, which can lead to scarring of the liver. Scarring of the liver is a potentially life-threatening condition called cirrhosis.
Key factors that are driving the growth of this market are the rising prevalence of NASH and increasing initiatives for the awareness of NASH. Additionally, the growing clinical trials involving combination studies of drugs is likely to emerge as a significant future trend in the market during the forecast period.
The CAGR value of the non-alcoholic steatohepatitis (NASH) market during the forecasted period of 2021–2028 is 47.1%.
The product segment of the non-alcoholic steatohepatitis (NASH) market is segmented into vitamin E and pioglitazone, ocaliva, elafibranor, selonsertib & cenicriviroc, and others. In 2021, the others segment held the largest share of the market, by product. The selonsertib & cenicriviroc segment of the non-alcoholic steatohepatitis (NASH) market is expected to witness growth in its demand at the fastest CAGR of 73.3% from 2024 to 2028.
The treatment segment dominated the global non-alcoholic steatohepatitis (NASH) market and accounted for the largest market share of 84.90% in 2021.
The retail pharmacy segment dominated the global non-alcoholic steatohepatitis (NASH) market and accounted for the largest market share of 61.39% in 2021.
The non-alcoholic steatohepatitis (NASH) market majorly consists of players such as Genfit SA; One Way Liver, S.L.; BioPredictive S.A.S.; Cadila Pharmaceuticals Ltd.; Prometheus Laboratories; Siemens Healthineers AG; Intercept Pharmaceuticals, Inc.; Novartis AG; Galmed Pharmaceuticals; and Laboratory Corporation of America Holdings amongst others.
Intercept Pharmaceuticals, Inc and Genfit SA are the top two companies that hold huge market shares in the non-alcoholic steatohepatitis (NASH) market.
North America held the largest market share for non-alcoholic steatohepatitis in 2021. The United States held the largest market in North America for non-alcoholic steatohepatitis, and the market is expected to grow due to increasing adoption of technological advancements and rising emphasis on improving treatment outcomes are projected to accelerate the growth of the non-alcoholic steatohepatitis market.
The presence of nonalcoholic fatty liver disease (NAFLD) and NASH in patients with COVID-19 is likely to cause them to be prone to severe forms of liver injury. Given the high prevalence of NAFLD worldwide, it's far critical to recognize the results of COVID-19 in such patients, which include the role of comorbidities, disease progression, and the severity of COVID-19. The presence of fibrosis rather than NASH/NAFLD is associated with worse clinical outcomes and higher mortality in COVID-19 patients. Additionally, there seems to be an increased likelihood of liver injury in NAFLD patients with COVID-19.
NASH had the strongest association with COVID-19 of all comorbid metabolic conditions, including hypertension and obesity. As the world keeps confronting the novel coronavirus pandemic, the impact of COVID-19 on specific patient populations, which includes people with diabetes, obesity, fatty liver disease, and NASH, has proven the need of providing actionable recommendations to clinicians and patients to offer optimal care and avoid needless deaths. The Global Liver Institute is committed to operating with researchers and innovators worldwide to evaluate and inform a strong response to this pandemic rapidly. As the push to combat NAFLD and NASH continues, research indicates that the anticipated relationship with weight problems is stark. Individuals with signs and symptoms of underlying fatty liver disease and NASH are at higher risk and infectious for longer for COVID-19. Therefore, COVID-19 is affected positively on the growth of the market.
- Genfit SA
- One Way Liver, S.L.
- BioPredictive S.A.S
- Cadila Pharmaceuticals Ltd.
- Prometheus Laboratories
- Siemens Healthineers AG
- Intercept Pharmaceuticals, Inc.
- Novartis AG
- Galmed Pharmaceuticals
- Laboratory Corporation of America Holdings
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published and advised several client across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organization are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Related Reports
Apr 2022
Aquatic Veterinary Market
Size and Forecast (2020 - 2030), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Type (Diagnostics and Treatments), Species (Fish, Crustaceans, Mollusca, and Others), Disease Source (Bacteria, Viruses, Parasites, and Others), Route of Administration (Water Medication, Medicated Feed, and Others), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
Apr 2022
Sickle Cell Disease Treatment Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis By Treatment (Generic Drugs and Originators), Route of Administration (Oral and Parenteral), and Distribution Channel (Direct Tender, Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others)
Apr 2022
Malaria and Sickle Cell Disease Treatment Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Treatment [Malaria and Sickle Cell Disease (SCD)], Route of Administration (Oral and Parenteral), and Distribution Channel (Direct Tender, Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others)
Apr 2022
Pharmaceutical Contract Sales Organizations Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Services (Commercial Services and Non-Commercial Services), Modules (Syndicated Modules and Dedicated Modules), Therapeutic Area (Cardiovascular Disorders, Oncology, Metabolic Disorders, Neurology, Orthopedic Diseases, Infectious Diseases, and Others), End User (Biopharmaceutical Companies and Pharmaceutical Companies), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
Apr 2022
Breast Cancer Therapeutics Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Drug Therapy [Targeted Drug Therapy (Abemaciclib, Ado-Trastuzumab Emtansine, Palbociclib, Trastuzumab, and Other Target Drug Therapies), Hormonal Drug Therapy (Selective Estrogen Receptor Modulators, Aromatase Inhibitors, and Selective Estrogen Receptor Downregulators), Chemotherapy, and Immunotherapy/Biological Therapy], Breast Cancer Type (Hormone Receptor, HER2+, and Triple-Negative Breast Cancer), Distribution Channel (Hospital Pharmacies, Drug Stores and Retail Pharmacies, and Online Pharmacies), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
Apr 2022
Radioactive Tracer Market
Size and Forecast to 2030 - Global Analysis by Tracer Type [Technetium-99m & Tc-97m, Iodine-131, Iron-59, Lutetium-171, Rubidium (Rb-82) Chloride & Ammonia (N-13), Scandium-46, Seaborgium-269, Hassium-269, Gallium Citrate Ga 67, Prostate-Specific Membrane Antigen (PSMA) (Ga-68), FDDNP (F-18) & FDOPA (F-18), Phosphorus-32 & Chromium-51, Thallium-201, F-18 FDG, F-18 FAPI, Ga-68 FAPI, F-18 PSMA, DOTATOC/DOTANOC/DOTATATE (Ga-68), and Others], Test Type (PET, SPECT, and Others), Application (Oncology, Pulmonary, Neurology, Cardiology, and Others) End User (Hospitals & Clinics, Diagnostic Centers, Academic & Research Institutes, And Others), and Geography
Apr 2022
Glioma Treatment Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Disease (Astrocytoma, Oligoastrocytoma, and Oligodendroglioma), Treatment Type (Surgery, Chemotherapy, Radiation Therapy, and Others), Grade (Low Grade and High Grade), End User (Hospital & Clinics and Ambulatory Surgical Center), and Geography
Apr 2022
Hyperpigmentation Disorder Treatment Market
Size and Forecast (2020 - 2030), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Treatment Type (Cosmeceutical, Light or Laser Therapy, Microdermabrasion, Chemical Peels, Cryotherapy, and Others), Condition (Melasma, Solar Lentigines, Post-Inflammatory Hyperpigmentation, and Others), End User (Hospitals, Dermatology Centers, and Others), and Geography (North America, Europe, Asia Pacific, South & Central America, and Middle East & Africa)